Our vision is to improve the treatment of severe diseases. Working with the medicines of the future we focus on oncology.

Human Health

Human HealthOur main goal is to develop new pharmaceuticals with high versatility were there are wide-spread medical needs.

Further reading »


Animal Health

Animal HealthAnimal Health develops and improves existing medical treatments focusing on oncology.

Further reading »


The Share

Latest News

Oasmia’s lead human oncology product Paclical shows a positive risk/benefit profile versus standard treatment in pivotal phase III clinical study

October 21 2014
Submission for European marketing approval of Paclical in 2015
Further reading »

Communiqué from Oasmia’s Annual General Meeting 2014

October 1 2014
Oasmia Pharmaceutical AB (publ.), with VAT no SE556332-667601, held its Annual General Meeting for the fiscal year 2013/2014 on Monday, September 29, 2014, where and the following main resolutions were made. For detailed information about the content of the resolutions, see the complete notice for Annual General Meeting which is available on Oasmia’s website www.oasmia.com, together with the complete proposals for the resolutions below.
Further reading »

Oasmia receives a new MSEK 40 bank loan

September 30 2014
Further reading »

bottom